Best EDC Software in 2026: 13 Platforms Compared by Study Type

Which EDC platform should you choose in 2026?

No single EDC platform fits every study. The choice follows one question: does your next study need enterprise-scale governance, a platform live in weeks, or full control over your own data model? Datacapt answers the second case, with EDC, ePRO, eConsent and randomization on one patient record, a study built by configuration instead of development, and EU data hosted in France on SecNumCloud-qualified infrastructure.

The thirteen platforms below are grouped by the studies they fit, from the platforms that mid-size sponsors and CROs shortlist most often to the enterprise systems that anchor global programs. Every entry states what the platform does well and where it stops, Datacapt included. This comparison covers the electronic data capture (EDC) capability of each platform, whatever else the vendor sells around it.

Every claim about a platform in this comparison comes from that vendor's public product pages, checked in September 2026. Datacapt publishes this comparison and includes its own platform, with its limitations stated alongside the others.

How the EDC market splits in 2026

The eClinical market has polarized. Large global programs still run on enterprise platforms built for scale and long-term standardization. Mid-size biotech, medical device sponsors and CROs now shortlist on a different basis: how fast a study goes live, how much internal expertise the platform demands, and whether the price holds over the study's real duration.

Buyers have also stopped looking for one system that does everything. They assemble what they need and expect the parts to exchange data, which makes interoperability the first technical question of any evaluation.

A third shift arrived with the current generation of platforms. Most vendors in this comparison now sell automation inside the EDC, from study setup and CDASH mapping to query drafting and data review. The claim no longer separates one platform from another. What separates them is which step the software performs, who validates the output, and where the audit trail records that decision.

| Group | What it is built for | Platforms |

| Mid-market | Fast study build, configuration instead of development, predictable pricing | Datacapt, Captivate, Castor, Clinion, Curebase, Medrio, Octalsoft, Viedoc |

| Enterprise | Global scale, deep ecosystem integration, complex multi-country programs | Medidata Rave, Oracle Clinical One, Veeva Vault EDC |

| Academic and investigator-led | Control over the data model, non-commercial research, limited budget | OpenClinica, REDCap |

Specialized vendors such as Climedo also appear in device and decentralized evaluations. The thirteen platforms below are the ones that come up most often in a shortlist.

Mid-market platforms: sponsors and CROs that need a study live fast

Datacapt

Datacapt is built for sponsors and CROs that need speed and regulatory rigor without the structural weight of legacy enterprise systems. The platform is cloud-native and carries no legacy technical debt. EDC, ePRO, eConsent, randomization, medical coding, trial supply and site operations run on one database, so a patient's clinical data, questionnaires and consent live in the same record.

Among the thirteen platforms in this comparison, Datacapt is the only one that publishes EU data hosting on SecNumCloud-qualified infrastructure, the French state qualification for cloud providers issued by ANSSI. For medical device and biotech sponsors running EU MDR investigations, that pairs European data residency with EDC, ePRO, eConsent and randomization on a single patient record, and studies go live in hours or days rather than months.

Strengths

• A visual builder where clinical teams build, test and deploy a study without custom programming. A trained team configures a straightforward study in hours. Epilepsia Waves, with no prior technical experience, configured, tested and deployed a 250-patient study in four days, and Synapse Medicine built its study in three weeks.
• Complex visit structures and protocol-specific logic without custom development
• One connected patient record across EDC, ePRO, eConsent and randomization, instead of separate systems to reconcile
• EU customer data hosted in France on SecNumCloud-qualified infrastructure, a qualification issued by ANSSI, with AWS regions available for sponsors who need them
• Built for EU MDR clinical investigations, with ISO 27001, HDS, ICH GCP, FDA 21 CFR Part 11 and GDPR compliance published on the platform
• Integrated data review and query management
• An AI agent turns the schedule of assessments into a draft eCRF in minutes and drafts the UAT scripts against the configuration it just created, with CDISC CDASH-aligned item suggestions: around 60% less time on the study build
• The agent writes in DRAFT only, never on a live study, its origin is recorded in the audit trail, and a person signs off before anything reaches production
• AI exposed through the Model Context Protocol, an open standard, so a sponsor runs the Datacapt agent or connects its own model
• Instant translation of eCRFs, ePROs, queries and study content for international studies
• One price per study, or an annual licence for a portfolio, with unlimited users on every plan and no implementation fee

Limitations

• Smaller global footprint than long-established enterprise vendors
• Not built for ultra-large, multi-program pharma standardization

Published results

• Median Technologies runs more than 220 studies across more than 2,500 clinical sites in more than 26 countries on Datacapt.
• Zurko Research runs more than 300 studies a year on Datacapt and completes them 40% to 45% faster.
• CIDP runs more than 100 studies a year and saved 40% of its study time after moving eCRF, ePRO and eConsent onto one platform.
• Artha Research cut clinical staffing by 50% and runs 100% of its studies on Datacapt.
• CHRU Strasbourg trained its teams in one to two hours, cut tasks that used to take days down to one hour, and 85% of questionnaires were completed by patients themselves.
• Epilepsia Waves configured, tested and deployed a survey to 250 patients in four days without writing code, and reached a 92% completion rate in the first phase.

Best for medical device and biotech sponsors, mid-market CROs, and studies that need a validated platform live fast.

Captivate (formerly ClinCapture)

ClinCapture, Inc. renamed its platform Captivate in 2026. The suite covers EDC, ePRO and eConsent, randomization and trial supply management, medical coding and trial master file, with professional services alongside.

Strengths

• No-code building of CRFs, edit checks and workflows
• One vendor across data capture, patient-facing collection, randomization and coding
• Established presence with medical device and pharmaceutical sponsors

Limitations

• The rename splits the platform's public track record between two names, so reviews, references and documentation published before 2026 carry the ClinCapture name
• The suite covers capture, patient-facing collection, randomization, coding and trial master file, with no CTMS for site operations

Best for sponsors and CROs that want one vendor across capture, patient-facing collection and randomization.

Castor

Castor started in academic research and stayed close to teams that build their own studies. It has since built dedicated products for patient registries and for post-market clinical follow-up (PMCF) under EU MDR 2017/745.

Strengths

• High autonomy for study builders
• Decentralized and direct-to-patient data collection
• Accessible documentation

Limitations

• The platform published on Castor's own product pages covers EDC and CDMS, eCOA and ePRO, eConsent and AI data extraction. Randomization, trial supply and site operations sit outside it, so a randomized study runs a second system.
• Study building runs alongside Castor Academy training and certification, and Castor's own data management service builds and cleans studies for teams that would rather not
• Governance and enterprise standardization features are less structured than on large enterprise platforms

Best for academic research, patient registries, PMCF studies and agile clinical teams.

Clinion

Clinion sells an eClinical suite built around automation, covering EDC, CTMS, RTSM, ePRO, eConsent, eSource and eTMF. Study setup, CDASH mapping, remote source data verification, medical coding and data review each carry an automated component.

Strengths

• Automation applied across the trial lifecycle rather than one module
• CDASH mapping handled inside the platform
• Broad module coverage under one vendor

Limitations

• Automation at every step puts the weight of the evaluation on what a person reviews and signs
• Delivery and support run from the United States, India and the United Kingdom

Best for sponsors and CROs that want automation across the full lifecycle from one vendor.

Curebase

Curebase runs recruitment, eConsent, eCOA and ePRO, participant engagement and EDC on one platform, with a separate product for research sites. The company started in decentralized research and now sells to biotech, pharmaceutical, medical device sponsors and CROs.

Strengths

• Recruitment and participant engagement sit in the same platform as data capture
• Direct-to-participant collection built into the core product
• Separate site-facing product for research sites

Limitations

• The platform is built around recruitment and engagement as much as data capture, so a study that needs capture alone takes on a wider scope
• The published product range covers recruitment, eConsent, eCOA and ePRO, EDC, coding and reporting. Randomization, trial supply and site operations sit outside it.

Best for studies that recruit, consent and follow participants outside a traditional site network.

Medrio

Medrio covers EDC, eCOA and ePRO, eConsent, randomization, CTMS and trial master file, with data services alongside the software. Early-phase research built its reputation, and the current range reaches medical device, pharmaceutical, biotech and animal health studies.

Strengths

• Configuration without programming, with spreadsheet-style logic instead of scripting
• Efficient study build for Phase I and Phase II
• Site-centric workflows

Limitations

• Very large global programs call for governance the platform does not impose on its own

Best for early-phase research, animal health studies, and CROs running fast development programs.

Octalsoft

Octalsoft sells a broad clinical and life sciences suite: EDC, CTMS, IWRS and RTSM, eTMF, ePRO and eCOA, remote source data verification, plus laboratory, quality and hospital systems.

Strengths

• Wide module coverage from one vendor
• Remote source data verification in the core suite
• Delivery model built around configuration and custom development

Limitations

• The catalogue reaches beyond clinical trials, so scoping the clinical stack takes a defined perimeter at contract stage
• Delivery runs from the United States and India

Best for sponsors and CROs that want one vendor across trial systems and adjacent laboratory or quality systems.

Viedoc

Viedoc is an established cloud EDC with a European footprint and a broad module range: EDC, ePRO, televisits, randomization and trial supply, medical coding, eTMF and a post-market surveillance product for the Japanese market.

Strengths

• Workflows investigators and monitors already know
• Module range spanning ePRO, televisits, randomization, trial supply, medical coding and eTMF
• Established across several geographies, including Japan-specific post-market requirements

Limitations

• Viedoc publishes an average study build time of ten weeks
• The product range lists eSignature but no eConsent module, so a study that collects patient consent electronically runs it on a second system
• Building studies in-house runs through Viedoc Study Build Certification, an online program that certifies named study design representatives. Viedoc also sells a study design review service and a study build service, so three separate offers surround the act of configuring a study.

Best for mid-size sponsors and CROs running studies with traditional, stable protocols across several geographies.

[[cta]]

Enterprise platforms: global, multi-country programs

Medidata Rave EDC

Medidata Rave remains the reference for large pharmaceutical organizations running complex global trials. Its position rests on scale, installed base and the breadth of the surrounding ecosystem.

Strengths

• Long track record on multi-country programs and with regulators worldwide
• Rave sits at the centre of the wider Medidata platform, which aggregates and reconciles data from eConsent, eCOA, RTSM and imaging
• Medidata states that protocol amendments and mid-study changes run without downtime
• A lighter edition, Rave Lite, targets Phase I and Phase IV studies

Limitations

• High total cost of ownership
• Building studies in-house means going through the Rave EDC Certified Study Builder path, which recommends at least three months of hands-on study building before the assessments and estimates the mock study build alone at 25 to 40 hours. Medidata states that certification is not required to build studies.
• Significant administrative and operational overhead on simple protocols

Best for large pharmaceutical sponsors and multi-country programs with centralized oversight.

Oracle Clinical One

Oracle sells Clinical One as one platform for data collection, randomization and trial supply management. Oracle positions the data collection module beyond EDC alone, on collecting data from any source and harmonizing it in one place.

Strengths

• Data collection, randomization and trial supply management on one platform
• Built for data-intensive programs and large datasets
• Recent releases add interoperability with electronic health record systems and data collection at the site

Limitations

• Steeper learning curve for sites and study teams
• Longer implementation timelines than lighter platforms

Best for large registries and trials with high data-point density over long durations.

Veeva Vault EDC

Veeva Vault EDC operates inside Veeva's clinical, quality and regulatory suite. Sponsors adopt it as part of a single-vendor standardization strategy. Veeva positions the product on faster study builds, faster mid-study changes and the removal of custom functions from study design.

Strengths

• Native alignment with the other Veeva Vault applications
• Strong validation and compliance framework
• Study design without custom functions, which shortens revalidation when a protocol changes

Limitations

• Contractual and pricing rigidity
• Less flexible for organizations that run part of their stack elsewhere

Best for large sponsors standardizing their clinical and regulatory technology on one vendor.

Academic and investigator-led research

OpenClinica

OpenClinica grew out of an open-source project and now sells a commercial subscription platform covering EDC, eConsent, eCOA, randomization, EHR-to-EDC and reporting. Study building runs on drag-and-drop tools and templated CRFs, with the option of a study built by the vendor.

Strengths

• Drag-and-drop study building with templated CRFs
• EHR-to-EDC in the core product
• Vendor-built study option for teams without a data manager

Limitations

• The project moved from open-source distribution to a commercial subscription, so a team expecting a free self-hosted edition should confirm what the current licence covers
• OpenClinica describes its platform as EDC, eConsent, eCOA, randomization, EHR-to-EDC, analytics and patient recruitment, so medical coding, trial supply and site operations sit outside it

Best for academic research organizations, investigator-initiated studies, and sponsors that want a supported platform without an internal build team.

REDCap

REDCap is developed by Vanderbilt University with support from the NIH and distributed at no cost to not-for-profit institutions that join the REDCap Consortium. Each institution installs and hosts it, which gives a research team full control over its own system.

Strengths

• No licence cost for institutions that are consortium members
• Full control over hosting and over the data model
• Wide adoption across academic research, which makes internal expertise easy to find

Limitations

• Compliance depends on how the institution builds its environment. The project states that REDCap can be installed in a variety of environments for compliance with standards such as HIPAA, 21 CFR Part 11 and FISMA, which leaves the validation and the infrastructure to the institution.
• Installation, hosting and maintenance call for internal IT capacity
• No commercial support contract

Best for academic teams with internal IT capacity and investigator-initiated studies. A study feeding a regulatory submission calls for the institution to validate its own installation first.

Which platform fits your study

| Your operational priority | What the study looks like | Platforms often shortlisted |

| A study live fast in a mid-size program | Sponsors and CROs balancing structure, adaptability and study speed | Datacapt, Captivate, Castor, Clinion, Curebase, Medrio, Octalsoft, Viedoc |

| Enterprise governance and large-scale standardization | Multi-country programs, centralized oversight, long-term portfolio management | Medidata, Oracle, Veeva |

| EU MDR investigations, post-market follow-up and EU data residency | Device studies under EU MDR 2017/745, registries, European sponsors with data residency requirements | Datacapt, Castor, Viedoc |

| Recruitment and direct-to-participant collection | Studies that recruit, consent and follow participants outside a traditional site network | Castor, Curebase |

| Early-phase, fast-moving programs | Phase I and Phase II with short build cycles | Clinion, Medrio, Viedoc |

| Automation across the study lifecycle | Teams that want setup, mapping, coding and data review assisted by software | Datacapt, Clinion, Medidata |

| Academic and investigator-led research | Configuration autonomy, limited budget, no dedicated data manager | Datacapt, Castor, OpenClinica, REDCap |

How to run the evaluation

Five questions separate platforms faster than a feature grid.

Ask for a build on a section of your own protocol. A stock demo shows the platform at its best on a study someone else designed. Your own visit schedule shows what the configuration model can and cannot absorb.

Ask what happens to the data already collected when the protocol changes. A Tufts CSDD study of 950 protocols found that 76% undergo at least one amendment. Editing a form is the easy part. Ask what becomes of the records already entered against the previous version: whether they stay readable and analyzable in one dataset, or whether the study ends up carrying two datasets that a data manager reconciles by hand at every reporting cycle.

Ask who validates what the automation produces. Most vendors on this list now sell automation inside the EDC. The claim tells you little on its own. Ask which step the software performs, what a person sees before it applies, and where the audit trail records the decision. A vendor who cannot answer at that level of detail is selling the category rather than a capability.

Ask for a reference on a study of your type and size. A reference on a global Phase III says little about a 12-site device investigation, and the reverse holds too.

Check the pricing model against your real duration. A price sized for a two-year trial fits a two-year trial. A registry or a post-market program with no defined end date needs a model that survives it.

Our method article covers this sequence in more depth: how to choose an EDC for your clinical trial. For the features that matter inside a platform, see the six essential EDC features. CRO teams have a dedicated comparison: best EDC software for CROs.